Ceftobiprole medocaril + Daptomycin
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Staphylococcus Aureus Bacteremia
Conditions
Staphylococcus Aureus Bacteremia
Trial Timeline
Aug 26, 2018 → Mar 11, 2022
NCT ID
NCT03138733About Ceftobiprole medocaril + Daptomycin
Ceftobiprole medocaril + Daptomycin is a phase 3 stage product being developed by Basilea Pharmaceutica for Staphylococcus Aureus Bacteremia. The current trial status is completed. This product is registered under clinical trial identifier NCT03138733. Target conditions include Staphylococcus Aureus Bacteremia.
What happened to similar drugs?
2 of 3 similar drugs in Staphylococcus Aureus Bacteremia were approved
Approved (2) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
17
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03138733 | Phase 3 | Completed |
Competing Products
12 competing products in Staphylococcus Aureus Bacteremia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Dalbavancin + Vancomycin + Oxacillin + Flucloxacillin + Cefadroxil + Clindamycin | AbbVie | Phase 3 | 40 |
| AZD7760 | AstraZeneca | Phase 1/2 | 39 |
| V710 + Placebo | Merck | Phase 2/3 | 30 |
| Daptomycin | Merck | Phase 2 | 35 |
| Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) | Merck | Phase 2 | 35 |
| Imipenem/cilastatin | Pfizer | Approved | 39 |
| linezolid (Zyvox) + vancomycin | Pfizer | Approved | 43 |
| Linezolid + Vancomycin | Pfizer | Pre-clinical | 26 |
| Aurexis® | Bristol Myers Squibb | Phase 2 | 35 |
| Aurexis® (tefibazumab) | Bristol Myers Squibb | Phase 2 | 35 |
| blood samples + nasal swabs | Sanofi | Pre-clinical | 26 |
| 514G3 (2 mg/kg) plus standard IV antibiotic treatment + 514G3 (10 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II | XBiotech | Phase 1/2 | 22 |